title: [Percutaneous closure of patent foramen ovale, as secondary prevention of cryptogenic cerebral event].
abstract: In patients with patent foramen ovale and cryptogenic stroke, the risk of recurrent event is about 4-5% yearly, despite of the antithrombotic treatment. Transcatheter closure of patent foramen ovale has been shown to decrease risk of recurrence. This report summarizes the first experiences in Hungary and the medium term follow up of our patients. Thirty-three patients were selected for closure. All the patients had at least one ischemic stroke, transitory ischemic attack or peripheral embolus. In 31 of them the stroke was confirmed by computer tomographic or magnetic resonance imaging. Patent foramen ovale with right-to-left shunt was diagnosed by transesophageal echocardiography. Transcatheter closure was performed under fluoroscopic and transesophageal echocardiographic control. Closure was successful in 31 patients. Passage of atrial septum did not succeed in two cases. An AV fistula at puncture site was the only early complication. There was no late complication. No device dislocation, periprocedural arrhythmia or embolic event was detected. No residual shunt could be found. During follow up of 11.3 (1-30) months no recurrent embolus was detected. Transcatheter closure of patent foramen ovale is a safe and efficient procedure to decrease the risk of recurrent ischemic events.
authors.affiliation: Gottsegen György Országos Kardiológiai Intézet, Budapest. temes@kardio.hu
authors.forename: András
authors.initials: A
authors.lastname: Temesvári
authors.forename: Olga Hajnalka
authors.initials: OH
authors.lastname: Bálint
authors.forename: Csilla
authors.initials: C
authors.lastname: Liptai
authors.forename: Sándor
authors.initials: S
authors.lastname: Kancz
authors.forename: Balázs
authors.initials: B
authors.lastname: Németh
authors.forename: András
authors.initials: A
authors.lastname: Szatmári
mesh_terms: D000328:Adult; D000368:Aged; D002545:Brain Ischemia / Q000150:complications* / Q000209:etiology; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000379:methods; D017548:Echocardiography, Transesophageal; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D005471:Fluoroscopy; D005500:Follow-Up Studies; D006344:Heart Septal Defects, Atrial / Q000150:complications* / Q000628:therapy*; D006801:Humans; D006814:Hungary; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents